Form 4: Abpro Holdings CEO Acquires 500,000 Restricted Stock Units

Abpro Holdings, Inc. CEO and Chairman, Suk Jin Wook (Miles), acquired 500,000 Restricted Stock Units, increasing his beneficial ownership to 646,477 shares.

Summary

• Suk Jin Wook (Miles), the CEO and Chairman of Abpro Holdings, Inc., acquired 500,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on July 25, 2025.
• The acquisition price for these RSUs was $0 per unit.
• Following this transaction, Suk Jin Wook (Miles) beneficially owns a total of 646,477 shares of Abpro Holdings, Inc. common stock.
• The 500,000 RSUs are scheduled to vest in three equal annual installments on each anniversary of March 3, 2025.
• Vesting is contingent upon BioCelsus International Inc.'s (the "Consultant") service continuing through and on each respective vesting date.
• The RSUs were issued to Suk Jin Wook (Miles) as the designee of the Consultant.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of Restricted Stock Units by the CEO and Chairman indicates a strong alignment of management's long-term interests with the company's performance and shareholder value, which is generally viewed positively by the market.

Positives

• CEO and Chairman Suk Jin Wook (Miles) increased his beneficial ownership in Abpro Holdings, Inc. by acquiring 500,000 Restricted Stock Units, demonstrating continued commitment to the company.
• The acquisition of RSUs at a $0 price point aligns management's long-term incentives with shareholder value through future vesting.

Negatives

• No explicit negatives identified in this Form 4 filing.

Risks

• The vesting of the 500,000 Restricted Stock Units is contingent upon BioCelsus International Inc.'s service continuing through each vesting date, introducing a condition to the full realization of the award.

Future Outlook

The 500,000 Restricted Stock Units are scheduled to vest in three equal annual installments on each anniversary of March 3, 2025, subject to the Consultant's continued service.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing primarily details an insider equity transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are reported in this filing.

Related Party Transactions

• The 500,000 Restricted Stock Units were issued to Suk Jin Wook (Miles) as the designee of BioCelsus International Inc. (the "Consultant"), with vesting contingent on the Consultant's service.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership by the CEO and Chairman through RSU grants aligns management's long-term incentives with shareholder interests, potentially fostering confidence.
• Employees: The RSU grant is part of an equity incentive plan, which can be a positive signal for employee compensation and retention strategies.

Next Steps

• The 500,000 Restricted Stock Units will vest in three equal annual installments on each anniversary of March 3, 2025, contingent on the Consultant's service.

Key Dates

Recommendation

The filing details a significant Restricted Stock Unit grant to the CEO and Chairman, aligning management's long-term interests with shareholder value. While this is a positive signal of insider commitment, a Form 4 alone does not provide sufficient comprehensive financial or operational data to warrant a 'buy' or 'sell' recommendation. Investors should consider this information in conjunction with the company's broader financial performance, strategic outlook, and market conditions.

Keywords

Abpro Holdings, ABP, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, CEO, Equity Incentive Plan, Corporate Governance